Reinfusion and serial measurements of XXXX -mobilized peripheral-blood progenitor cells in @entity1 receiving multiple cycles of high-dose chemotherapy.

@entity1 @entity3003 @entity1503 @entity1398 @entity2280 @entity2841
PURPOSE: To examine the ability of @entity3003 to mobilize peripheral-blood progenitor cells (PBPCs) and to examine the impact of infusing these cells on myelosuppression following multiple cycles of high-dose therapy. Fluctuations in circulating progenitor cell concentration following repeated cycles of this therapy were also measured. @entity1 AND METHODS: Eight @entity1 received a total of 20 cycles of @entity3003 1,200 mg/m2 per course, @entity2841 ( @entity2841 ) 5 micrograms/kg/d, and PBPC reinfusion every 28 days. PBPC were collected following 1 week of @entity2841 and following the first and second cycles of chemotherapy. @entity1503 was correlated with the number of progenitor cells reinfused per cycle. The concentration of PBPC per milliliter of blood was measured at study entry, following @entity2841 priming, and after each cycle of chemotherapy. RESULTS: We observed a strong inverse correlation between the number of PBPCs ( @entity2280 and colony-forming unit granulocyte-macrophage [CFU-GM]), but not mononuclear cells (MNCs) reinfused and the days with @entity1398 less than 500/microL and platelets less than 20,000/microL. Compared with baseline levels, the circulating PBPC concentration increased up to 27-fold following the first course of chemotherapy, but decreased toward, and eventually below, baseline following the second and third cycles of @entity3003 . CONCLUSION: PBPC reinfusion directly correlated with a reduction in myelosuppression following high-dose @entity3003 chemotherapy. While high-dose @entity3003 plus @entity2841 leads to a substantially greater mobilization of PBPC than @entity2841 alone, this effect is lost after multiple treatment cycles. These results emphasize the importance of early procurement and value of PBPC reinfusion in conjunction with multiple cycles of dose-intensive chemotherapy.
